Month: May 2020

Comment by fund manager Viljar ArakasDue to the state of an emergency that started in the Baltics in the middle of March, it could have been expected that April will be the most difficult month of the year for the tenants of the fund. During the crisis, we have taken measures with our clients to mitigate the effects of the emergency situation, as a result of which the fund’s performance in April was better than we expected initially. There is a reason to believe that May will be even better for the fund’s tenants due to the easing of the reduction of movement and business activities restrictions.EfTEN Real Estate Fund III AS’s largest single investment is Saules Miestas Shopping Center in Šiauliai, Lithuania. Shopping centers in Lithuania were opened already on April 23, including the tenants of Saules Miestas. However,...

Fondijuht Viljar Arakas’e kommentaarSeoses märtsi keskpaigast alguse saanud eriolukorraga võis eeldada, et aprill kujuneb fondi üürnikele aasta kõige keerulisemaks kuuks. Oleme kriisiperioodil koos oma klientidega võtnud kasutusele meetmeid eriolukorra mõju leevendamiseks, mille tulemusel on fondi aprilli tulemused paremad kui me seda kuu alguses eeldasime. On alust uskuda, et mai kujuneb seoses liikumise ja äritegevuse piirangute vähendamisega fondi üürnikele veelgi paremaks. EfTEN Real Estate Fund III AS-i suurim üksikinvesteering on Saules Miestase kaubanduskeskus Šiauliais, Leedus. Leedus avati kaubanduskeskused juba 23. aprillil, s.h avasid kauplused ka Saules Miestase üürnikud. Sellegipoolest võtab kriisieelse keskuse külastatavuse ja käibe saavutamine hinnanguliselt 4 – 5 kuud aega. Leedu valitsus võttis mai alguses vastu üürikulude...

FY 2019/20 resultats presentationAttachment2020 05 12 – FY 2019-20 results presentation

présentation des résultats annuel 2019/20Pièce jointe2020 05 12 – FY 2019-20 results presentation

Cash, cash equivalents and financial assets of the Company amounted to €206.9 millioniFirst patient dosed in avdoralimab (anti-C5aR) Phase II clinical trial in COVID-19 patients with severe pneumoniaFirst patient dosed in IPH5201 Phase I clinical trial in advanced solid tumorsNew efficacy data from Phase Ib/II monalizumab and cetuximab combination in IO-pretreated head and neck patients to be presented at ASCO20 Virtual Scientific ProgramMARSEILLE, France, May 12, 2020 (GLOBE NEWSWIRE) — Innate Pharma SA (the “Company” – Euronext Paris: FR0010331421 – IPH; Nasdaq: IPHA) today announced its revenue and cash position for the three-month period ended March 31, 2020.“During this quarter, we have maintained momentum with our pipeline as well as ensuring business continuity despite this challenging and unprecedented time,” said...

Sarclisa® (isatuximab) Phase 3 IKEMA trial meets primary endpoint early in patients with relapsed multiple myelomaIKEMA trial results released early based on recommendation of an Independent Data Monitoring CommitteeAddition of Sarclisa significantly reduced the risk of disease progression or death compared to carfilzomib and dexamethasone aloneResults will be submitted to an upcoming medical meeting and form the basis for regulatory submissions later this yearPARIS – May 12, 2020 – The Phase 3 IKEMA clinical trial evaluating Sarclisa® (isatuximab) added to carfilzomib and dexamethasone met the primary endpoint at its first planned interim analysis, demonstrating significantly prolonged progression-free survival compared to standard of care carfilzomib and dexamethasone alone in patients with relapsed multiple myeloma. There were...

L’essai de phase III IKEMA consacré à Sarclisa® (isatuximab) atteint plus tôt son critère d’évaluation principal chez des patients présentant un myélome multiple en rechutePublication précoce des résultats de l’essai IKEMA sur les recommandations d’un Comité indépendant de suivi des donnéesL’ajout de Sarclisa a permis d’obtenir une réduction significative du risque de progression de la maladie ou de décès, comparativement à l’association carfilzomib et dexaméthasone seulementCes résultats seront présentés dans le cadre d’un prochain congrès médical et formeront la base de soumissions réglementaires dans le courant de l’annéePARIS – Le 12 mai 2020 – L’essai clinique de phase III IKEMA évaluant Sarclisa® (isatuximab) en association avec du carfilzomib et de la dexaméthasone a atteint son critère d’évaluation principal selon les résultats...

Cash, cash equivalents and financial assets of the Company amounted to €206.9 millioni First patient dosed in avdoralimab (anti-C5aR) Phase II clinical trial in COVID-19 patients with severe pneumoniaFirst patient dosed in IPH5201 Phase I clinical trial in advanced solid tumorsNew efficacy data from Phase Ib/II monalizumab and cetuximab combination in IO-pretreated head and neck patients to be presented at ASCO20 Virtual Scientific ProgramInnate Pharma SA (the “Company” – Euronext Paris: FR0010331421 – IPH; Nasdaq: IPHA) today announced its revenue and cash position for the three-month period ended March 31, 2020.“During this quarter, we have maintained momentum with our pipeline as well as ensuring business continuity despite this challenging and unprecedented time,” said Mondher Mahjoubi, Chief Executive Officer, Innate Pharma....